American Society of Hirudotherapy

Otolaryngology

International clinical evidence for hirudotherapy in hearing loss, sinusitis, and ENT disorders

Bleeding / Transfusion Risk
Aeromonas Infection Risk
Single-Use Only + Biohazard Disposal
Last Updated: May 27, 2026ASH Editorial · based on the booksTier C — Investigational / researchGRADE: Low
Ear replantation (FDA-aligned): FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Other ENT applications off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.

Ear replantation falls inside the K040187 FDA-cleared device indication; sinusitis, vasomotor rhinitis, and hearing loss are off-label. For tier-based clinical reasoning, see Clinical Knowledge Support.

Off-label

Off-label use — not FDA-cleared for this indication

Cleared indication: Otolaryngologic applications (sinusitis, hearing loss, vasomotor rhinitis, peritonsillar abscess)

Off-label prescribing is legal in the United States and remains a clinical decision. The discussion below is provided for educational context and does not represent an FDA-cleared indication.

Investigational Application

Otolaryngology is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

The middle ear, paranasal sinuses, and cochlea share end-arterial blood supply, narrow drainage, and fractional-millimeter tolerance for edema. ENT hirudotherapy is documented across 259+ patients in seven investigations (1990-2003): chronic SNHL (n=104), sinusitis (n=60), vasomotor rhinitis (n=55), cochleovestibular disorders (n=40), and inflammatory ear disease. No randomized controlled trial exists for any ENT indication.

Biological Rationale

Microcirculation & Anti-Inflammatory

Histamine-like vasodilator increases periauricular/paranasal capillary flow. Hyaluronidase facilitates lymphatic drainage. Eglins block elastase/cathepsin G; LDTI attenuates mast cell mucosal inflammation; C1s complement inhibitor modulates classical pathway — relevant to sinusitis and neuritis.

Anticoagulant & Lipid

Hirudin prevents fibrinogen clotting. Calin/saratin inhibit platelet adhesion. Destabilase-M lyses fibrin. Lipase and cholesterol esterase reduce circulating lipids. Together these target cochlear ischemia from vertebrobasilar atherosclerosis.

Rationale is strongest for vascular ENT disorders (cochlear ischemia, posterior circulation ischemia, hypercoagulable states), where multiple SGS components directly target pathophysiology.

Clinical Evidence

GRADE Evidence Level: Low

Observational studies or RCTs with serious limitations

Otolaryngology — International Clinical Evidence
StudyDesignPopulation (n=)InterventionKey OutcomeResult
Seleznev & Shchetinina
1990
Protocol guidelines + case seriesNeuritis, tinnitus, otitis, trigeminal neuralgia
(n=NR)
Protocol details in the clinician viewPain, audiometric noise, electroconductivityPain resolved 1-2 sessions; decreased tinnitus; shortened disability
In Baskova et al. guidelines; n not reported; Level IV
Grigoryev et al.
1998
Case seriesChronic otitis media with vascular comorbidity
(n=NR)
Protocol details in the clinician viewBlood biochemistry, neurological symptomsHypercoagulable profile corrected; neurological symptoms resolved
Vascular comorbidity mimicking otogenic complications; Level IV
Grigoryev & Krymskaya
1998
Case seriesCochleovestibular disorders, peripheral origin
(n=40)
Protocol details in the clinician viewTinnitus, head heavinessAll 40: reduced tinnitus; subjective lightness in head
Vascular etiology; bleeding up to 5h; Level IV
Zhuravsky
2000
Clinical-audiological study (candidate dissertation)Chronic SNHL: vascular, neurogenic, presbycusic, ototoxic
(n=104)
Protocol details in the clinician viewAudiometry, speech comprehension, histology (animal)Therapeutic effect (vascular/neurogenic); better speech comprehension without threshold change (presbycusis); reduced conductive and sensorineural loss (secondary to chronic middle-ear inflammation); nonspecific stabilizing effect (ototoxic/postinfectious)
Largest ENT study; preclinical histologic data; Level IV
Moskalenko
2001
Case seriesAcute sinusitis
(n=60)
Protocol details in the clinician viewHeadache, sinus puncture avoidance, antibioticsHeadache reduced; sinus puncture avoided; antibiotics eliminated
Clinically significant procedural sparing; Level IV
Krymskaya et al.
2003
Prospective cohortVasomotor rhinitis: idiopathic (20), drug-induced (35)
(n=55)
Protocol details in the clinician viewNasal breathing, medication need; 3-4 month follow-upImmediate improvement of nasal breathing; medication needed in only 3 hypertensive patients during treatment
AE: septal hematoma 1.8%, allergic rhinorrhea 9.1%; Level IV
Zhuravsky
2000
Animal histologic study (preclinical)Membranous labyrinth (animal model)
(n=NR)
Protocol details in the clinician viewHair cell activity, capillary density, neuroepitheliumEnhanced hair cells; increased stria vascularis capillaries; neuroprotection
Structural basis for audiometric improvements; preclinical
All ENT evidence is Level IV (case series, uncontrolled cohorts). No RCT has been performed. Sham leech devices used in other specialties could be adapted for periauricular application.

Inflammatory Ear Disease — Historical Report (unverifiable)

Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.

Pain resolved after 1-2 sessions in most cases. Audiometric testing showed decreased tinnitus intensity, skin electroconductivity increased, tissue oxygenation rose, and disability duration shortened.

Chronic Sensorineural Hearing Loss — uncontrolled Russian-language report that is not independently verifiable; no controlled trial exists

Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.

Vascular/Neurogenic

Audiometric threshold improvement. SGS anticoagulant/vasodilatory actions directly target cochlear ischemia from vertebrobasilar compromise. Strongest etiologic response.

Presbycusis

Improved speech comprehension without pure-tone threshold change — central neurovascular processing benefit rather than peripheral hair cell recovery.

Secondary (Middle Ear)

Reduction in both conductive and sensorineural components — combined mechanism via decongestion and microvascular improvement.

Ototoxic/Postinfectious

Nonspecific stabilization of remaining function — neuroprotective rather than regenerative effect.

Preclinical component: animal model histology showed enhanced hair cell activity, increased stria vascularis capillary density, and protective effect on spiral organ neuroepithelium — structural basis for the audiometric findings.

Cochleovestibular Disorders

Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.

Acute Sinusitis

Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.

Vasomotor Rhinitis

Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.

Outcomes

  • Immediate: Improvement or complete restoration of nasal breathing; disappearance of head heaviness; resolution of ear congestion
  • Follow-up (3-4 months): During the treatment period, medication was needed in only 3 hypertensive patients
  • Pain: No patient reported procedural pain (0/55)

Adverse Events

  • Septal hematoma: 1/55 (1.8%) — premature mucocapillary closure; requires prompt drainage
  • Allergic rhinorrhea: 5/55 (9.1%) — managed with antihistamines; treatment continued
  • 9.1% allergic rate appears elevated relative to reported cutaneous leech-therapy hypersensitivity rates, possibly from nasal mucosal immunoreactivity
Investigators recommended endonasal hirudotherapy as the therapy of choice for idiopathic and drug-induced vasomotor rhinitis — a strong recommendation given the limited alternatives for rhinitis medicamentosa. Based on Level IV evidence without a control group.

Clinical Protocol

Patient Selection & Pre-Procedure

Candidates include patients with otitis, auditory neuritis/tinnitus, chronic SNHL (vascular/neurogenic/presbycusic), acute sinusitis, vasomotor rhinitis, and cochleovestibular disorders with vascular comorbidity. All patients must receive concurrent standard ENT care. Pre-procedure workup: audiometry for hearing indications; sinus probing/lavage to exclude purulent sinusitis (mandatory before endonasal application); blood biochemistry (cholesterol, fibrinogen, prothrombin index); coagulation panel; vertebrobasilar Doppler for vascular etiology; medication review.

Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.

Post-Procedure

Sterile dressing (expect oozing up to 5h periauricular). Audiometric follow-up at course completion. Repeat sinus lavage for obstruction assessment. Blood biochemistry for vascular patients. Nasal septum check at 24-48h post-endonasal. Vasomotor rhinitis: 3-4 month reassessment.

Safety Considerations

  • Endonasal bleeding: Kiesselbach plexus = prolonged bleeding. Nasal packing must be available. Contraindicated with anticoagulants without risk-benefit assessment
  • Septal hematoma: 1/55 (1.8%); requires prompt drainage to prevent abscess, cartilage necrosis, saddle-nose deformity
  • Leech migration (nasal): Aspiration hazard if leech reaches nasopharynx. Syringe containment + continuous monitoring mandatory
  • Leech migration (ear canal): Limit to lateral cartilaginous canal; continuous visual monitoring to prevent tympanic membrane contact
  • Allergic rate: 9.1% endonasal vs 2-5% cutaneous; manage with antihistamines
  • Infection: Aeromonas hydrophila — nasal cavity proximity to sinuses/cavernous sinus. Prophylactic fluoroquinolone or TMP-SMX for endonasal use
  • Contraindications: Tympanic membrane perforation; active purulent sinusitis; uncontrolled anticoagulation; known Hirudo allergy; immunocompromise; pediatric patients (not studied)

Drug Interactions

  • Anticoagulants/antiplatelets: Additive bleeding. Relative contraindication endonasal; coagulation monitoring periauricular; nasal packing available
  • Nasal decongestants: Discontinue before endonasal (therapeutic for rhinitis medicamentosa)
  • Antihypertensives: Monitor BP; 25/55 rhinitis patients tolerated concurrent use
  • Prophylactic antibiotics: Consider fluoroquinolone/TMP-SMX for endonasal applications (Aeromonas prophylaxis)

Regulatory Status

No regulatory clearance exists for ENT leech applications in the US, EU, or other major jurisdictions. FDA 510(k) K132958 clearance of Hirudo verbana is limited to venous congestion in surgical flaps/replantation. All ENT applications are off-label. In Russia, hirudotherapy is included in ENT protocols at specialist clinics within the national complementary medicine framework.

Informed consent must address: investigational nature, absence of FDA clearance for ENT use, Level IV evidence base, and unique safety considerations of endonasal and ear canal application.

Evidence Gaps & Research Priorities

No RCT exists for any ENT indication. However, ENT disease offers standardized audiometric/imaging endpoints, quantifiable blood biomarkers, and established comparators (sinus puncture, decongestant withdrawal) that make rigorous investigation feasible. ASH supports development of controlled studies for:

  • Chronic SNHL (Priority 1): RCT of HT + standard care vs. standard care in vascular/neurogenic SNHL; audiometric primary endpoint; vertebrobasilar Doppler mechanistic endpoint
  • Acute sinusitis (Priority 2): Non-inferiority trial vs. maxillary sinus puncture; CT clearance endpoint; procedural burden and antibiotic use secondary
  • Vasomotor rhinitis (Priority 3): Controlled comparison vs. gradual decongestant withdrawal; rhinomanometry and medication-free days endpoints
  • Mechanistic studies (Priority 4): SGS effects on mucosal inflammation biomarkers (IL-6, TNF-alpha, mast cell tryptase) and cochlear blood flow (gadolinium MRI or OCT angiography)

Key Takeaways

Largest ENT evidence: 104 SNHL patients (Zhuravsky 2000) with audiometric + preclinical histologic data. A therapeutic effect was reported in chronic SNHL of vascular and neurogenic origin.

Vasomotor rhinitis: immediate improvement of nasal breathing; 3-4 month follow-up; medication needed in only 3 hypertensive patients during treatment. Recommended as therapy of choice (Krymskaya 2003).

Sinusitis: Sinus puncture avoided in 60 patients (Moskalenko 2001) — meaningful procedural sparing.

All Level IV: No RCTs, but ENT offers standardized audiometric/imaging endpoints for rigorous studies. Endonasal risks (migration, hematoma, 9.1% allergy) require specialized training.

Related Resources

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Otolaryngology — Investigational Hirudotherapy Applications | ASH